お知らせ • Oct 29
OS Therapies Incorporated Announces Appointments to Board of Directors
OS Therapies Incorporated announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Companys Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. Ms. McKean Dieser brings a deep execution experience in regulatory, pricing, commercialization, and patient engagement, while Mr. Jarry brings significant business development and fundraising expertise &relationships to the Company. As the company continue preparations to engage FDA regarding its potentially pivotal trial of its cancer immunotherapy OST-HER2 seeking to prevent metastasis in resected, recurrent osteosarcoma, the company is building up its internal infrastructure to prepare for regulatory approval and commercial launch in the United States, while evaluating strategic partnerships to bring the therapy to market outside the United States. Ms. McKean Dieser and Mr. Jarry are well positioned to help company achieve these objectives. The company thank Dr. Colin Goddard and Mr. Joacim Borg for the years of service to the Company, especially for their guidance in helping OS Therapies transition into a public company. Ms. McKean Dieser holds a global role as Vice President, Head of Legal Patient Evidence of UCB Inc. At UCB, she leads a team of attorneys supporting UCBs global assets,global payer functions, and regulatory, medical and patient communities, including clinical development. Ms. McKean Dieser was formerly a member of the AbbVie Inc. legal team providing global product support for the immunology and oncology franchises and was the government pricing lawyer for all pharmaceutical and combination products from May 2013 to July 2016. Prior to joining the pharmaceutical industry, Ms. McKean Dieser practiced corporate law in Atlanta, Georgia at two nationally recognized law firms. She earned her J.D. degree from The Catholic University Columbus School of Law and is admitted to practice law in the states of Georgia and Illinois. Prior to receiving her law degree, Ms. McKean Dieser received an M.A. in Public Administration from the University of Maryland, European Division and a B.A. degree in English Literature from Duquesne University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma in January 2024 at the age of 21. Mr. Jarry is the Co-founder and Chief Executive Officer of Libera Bio S.L. He also serves as the Chief Operating Officer of Advantage Therapeutics Inc. and as Chief Financial Officer of Rational Vaccines Inc. Mr. Jarry previously served as President and Chief Commercial Officer of DarioHealth (Nasdaq: DRIO) from October 2017 until January 2020. Between 2015 and 2016, he served as Senior Vice President of the Consumer Sector and Officer at Intrexon Corp. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operations and Market Access, focusing on Emerging Markets, for Bristol-Myers Squibb, where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular and diabetes. Prior to that, Mr. Jarry served as the Global Business Unit Head of Bayer Diabetes Care and in several leadership roles at Novartis International AG. Mr. Jarry holds a M.Sc. degree from Ecole Centrale de Paris, a MEng. degree from Dlgation Gnrale pour lArmement, and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science and Hautes tudes Commerciales Paris.